Cambridge-based biotechnology company pioneering the use of artificial intelligence to transform drug discovery and development. The company has developed a proprietary AI-driven platform that integrates multi-modal biological data to create virtual models of disease at the organ and organism level, enabling researchers to better understand disease mechanisms and identify promising therapeutic interventions. By combining systems biology, machine learning, functional genomics, and computational pharmacology, AI VIVO aims to accelerate the discovery of novel medicines and improve the efficiency of drug development for patients with unmet medical needs.